Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT04607148 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT04607148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04607148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
November 16, 2020
Completion date
November 14, 2022
Enrollment
144 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

geographic atrophy, macular degeneration, age-related